Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia, Myeloid, Acute 7Breast Neoplasms 7Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Recurrence 3Pancreatic Neoplasms 3Neuroblastoma 3Melanoma 3Medulloblastoma 3Lymphoma, Non-Hodgkin 3Congenital Abnormalities 3Carcinoma, Non-Small-Cell Lung 3Wilms Tumor 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2

Interventions

Cyclophosphamide 17Trastuzumab 16Paclitaxel 15Doxorubicin 11Docetaxel 10Radiotherapy 9Carboplatin 9Capecitabine 9Bevacizumab 8Lapatinib 7Taxes 6Tamoxifen 6Gemcitabine 5Filgrastim 5Chemotherapy, Adjuvant 5sargramostim 4Sorafenib 4Radiation 4Neoadjuvant Therapy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Vinorelbine 3Thiotepa 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3Irinotecan 3Immunohistochemistry 3Granulocyte Colony-Stimulating Factor 3Erlotinib Hydrochloride 3Anastrozole 3Albumin-Bound Paclitaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms, Male × tipifarnib × Clear all
NCT00054470 2012-06-29

Tipifarnib Plus Trastuzumab in Treating Patients With Metastatic Breast Cancer

The University of Texas Health Science Center at San Antonio

Phase 2 Withdrawn
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡